A Randomized Trial to Compare Dolutegravir Plus Boosted Darunavir Versus Recommended Standard of Care Antiretroviral Regimens in People With HIV-1, Whose First-line Non-nucleoside Reverse Transcriptase Inhibitor Therapy Has Failed: Final 96-week Results of the D2EFT Study. - Nyein PP; Borok M; Eriobu N; Kaplan R; Kumarasamy N; Avihingsanon A; Losso MH; Azwa I; Karyana M; Dao S; Cisse M; Andrade Villanueva JF; et al. (Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026)